{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:59:10Z","timestamp":1785351550797,"version":"3.55.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"DOI":"10.1007\/s11606-026-10556-7","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:22:08Z","timestamp":1785349328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of Statistics to Assess Serious Adverse Events in Clinical Trials of New Drugs: Cross-Sectional Study of FDA Review Memos"],"prefix":"10.1007","author":[{"given":"Sarah","family":"Tanveer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek A.","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Camelo","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Wastila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine E.","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P. A.","family":"Ioannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"6","key":"10556_CR1","doi-asserted-by":"publisher","first-page":"e036875","DOI":"10.1136\/bmjopen-2020-036875","volume":"10","author":"R Phillips","year":"2020","unstructured":"Phillips R, Cornelius V. Understanding current practice, identifying barriers and exploring priorities for adverse event analysis in randomised controlled trials: an online, cross-sectional survey of statisticians from academia and industry. BMJ Open. 2020;10(6):e036875. https:\/\/doi.org\/10.1136\/bmjopen-2020-036875","journal-title":"BMJ Open."},{"issue":"1","key":"10556_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0020731420979824","volume":"51","author":"J Lexchin","year":"2021","unstructured":"Lexchin J, Graham J, Herder M, Jefferson T, Lemmens T. Regulators, pivotal clinical trials, and drug regulation in the age of COVID-19. Int J Health Serv. 2021;51(1):5-13. https:\/\/doi.org\/10.1177\/0020731420979824","journal-title":"Int J Health Serv."},{"key":"10556_CR3","doi-asserted-by":"publisher","unstructured":"Tanveer S. Data files: Use of Statistics to Assess Serious Adverse Events in Clinical Trials of New Drugs: Cross-Sectional Study of FDA Review Memos. Published online June 23, 2025. https:\/\/doi.org\/10.17605\/OSF.IO\/284TQ","DOI":"10.17605\/OSF.IO\/284TQ"},{"key":"10556_CR4","unstructured":"Duke-Margolis Center for Health Policy, FDA. Public Workshop: Advancing Premarket Safety Analytics. Presented at: Virtual Workshop; September 14, 2022. https:\/\/healthpolicy.duke.edu\/sites\/default\/files\/2022-09\/Advancing%20Premarket%20Safety%20Analytics%20Final%20Slide%20Deck.pdf"},{"key":"10556_CR5","unstructured":"U.S. Food and Drug Administration. Draft Guidance: Benefit-Risk Assessment for New Drug and Biological Products Guidance for Industry.; 9\/2021. Accessed August 19, 2023. https:\/\/www.fda.gov\/media\/152544\/download"},{"key":"10556_CR6","unstructured":"U.S. Food and Drug Administration. MAPP 6010.4 Good Review Practice Statistical Review Template.; 2012."},{"issue":"5","key":"10556_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1177\/1740774511419165","volume":"8","author":"TA Hammad","year":"2011","unstructured":"Hammad TA, Pinheiro SP, Neyarapally GA. Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations. Clin Trials. 2011;8(5):559-570. https:\/\/doi.org\/10.1177\/1740774511419165","journal-title":"Clin Trials."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10556-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10556-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10556-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:22:09Z","timestamp":1785349329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10556-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":7,"alternative-id":["10556"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10556-7","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"29 July 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Wendy Camelo Castillo was supported in part by a research grant from the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp, unrelated to this work. Peter Doshi declares grants from the FDA (through University of Maryland M-CERSI; 2020) and Arnold Ventures (2017-22; 2025-26), and is Senior Editor, Investigations, The BMJ. Tarek Hammad is employed by Takeda Pharmaceuticals and own stock.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}